Literature DB >> 11239862

New corneal findings in human T-cell lymphotrophic virus type 1 infection.

R R Buggage1, G A Levy-Clarke, J A Smith.   

Abstract

PURPOSE: Human T-cell lymphotrophic virus type 1 is a RNA retrovirus that primarily affects CD4+ T-cells. Human T-cell lymphotrophic virus type 1 infection is the established cause of adult T-cell leukemia/lymphoma, an aggressive malignancy of CD4+ T-cells, and two nonneoplastic conditions: human T-cell lymphotrophic virus type 1-associated myelopathy/tropical spastic paraparesis and human T-cell lymphotrophic virus type 1 uveitis. Other reported ophthalmic manifestations of human T-cell lymphotrophic virus type 1 infection include lymphomatous and leukemic infiltrates in the eye and ocular adnexa in patients with adult T-cell leukemia/lymphoma, retinal pigmentary degeneration, and neuro-ophthalmic disorders in patients with human T-cell lymphotrophic virus type 1-associated myelopathy/tropical spastic paraparesis and keratoconjunctivitis sicca, episcleritis, and sclerouveitis in asymptomatic human T-cell lymphotrophic virus type 1 carriers. This report describes the ocular findings in three Jamaican patients with human T-cell lymphotrophic virus type 1 infection and adult T-cell leukemia/lymphoma.
METHODS: The clinical records of three patients with human T-cell lymphotrophic virus type 1 infection and adult T-cell leukemia/lymphoma examined at the National Eye Institute were reviewed. Each patient had one or more complete ophthalmic evaluations.
RESULTS: All three patients had corneal abnormalities, including corneal haze and central opacities with thinning; bilateral immunoprotein keratopathy; and peripheral corneal thinning, scarring, and neovascularization. All three patients had elevated serum immunoglobulin levels.
CONCLUSIONS: We believe that the novel corneal findings in these patients are most likely a consequence of the hypergammaglobulinemia induced by the human T-cell lymphotrophic virus type 1 infection or the T-cell malignancy.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11239862     DOI: 10.1016/s0002-9394(00)00881-3

Source DB:  PubMed          Journal:  Am J Ophthalmol        ISSN: 0002-9394            Impact factor:   5.258


  5 in total

1.  Study of autoantibodies in patients with keratoconjunctivitis sicca infected by the human T cell lymphotropic virus type 1.

Authors:  Ana Karina Ferraz-Chaoui; Ajax Mercês Atta; Maria Luiza Sousa Atta; Bernardo Galvão-Castro; Mittermayer B Santiago
Journal:  Rheumatol Int       Date:  2009-07-29       Impact factor: 2.631

2.  Successful treatment of young-onset adult T cell leukemia/lymphoma and preceding chronic refractory eczema and corneal injury by allogeneic hematopoietic stem cell transplantation.

Authors:  Fumiya Miyamura; Shinichi Kako; Hiroko Yamagami; Ken Sato; Miki Sato; Kiriko Terasako; Shun-Ichi Kimura; Hideki Nakasone; Satoko Aoki; Shinya Okuda; Rie Yamazaki; Kumi Oshima; Kentaro Yoshinaga; Takakazu Higuchi; Junji Nishida; Toshio Demitsu; Akihiro Kakehashi; Yoshinobu Kanda
Journal:  Int J Hematol       Date:  2009-08-25       Impact factor: 2.490

Review 3.  Systemic diseases and the cornea.

Authors:  Ruchi Shah; Cynthia Amador; Kati Tormanen; Sean Ghiam; Mehrnoosh Saghizadeh; Vaithi Arumugaswami; Ashok Kumar; Andrei A Kramerov; Alexander V Ljubimov
Journal:  Exp Eye Res       Date:  2021-01-21       Impact factor: 3.467

4.  Ocular manifestations and pathology of adult T-cell leukemia/lymphoma associated with human T-lymphotropic virus type 1.

Authors:  Melissa M Liu; Emiko Furusato; Xiaoguang Cao; Defen Shen; Chi-Chao Chan
Journal:  Rare Tumors       Date:  2010-12-31

5.  Revisiting Keratoconjunctivitis sicca associated with Human T-Cell Lymphotropic Virus Type 1: prevalence, clinical aspects and proviral load.

Authors:  Regina Helena Rathsam-Pinheiro; Ney Boa-Sorte; Maria Fernanda Rios Grassi; Úrsula Cury Copello; Karla Tayrine Silva Guimarães Rios; Thessika Araújo; Bernardo Galvão-Castro
Journal:  Braz J Infect Dis       Date:  2019-05-03       Impact factor: 3.257

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.